The latest news about Samsung Bioepis
• Located in Korea’s ‘Bio Cluster’ of Songdo in the Incheon Free Economic Zone (IFEZ)
• The 52,000-square-foot campus to become the hub of Samsung Bioepis’ drive for accelerated development of next-generation biologic medicines
• Includes ‘Welfare Center’ with cafeteria, in-house fitness center, and a daycare center
INCHEON, Korea – Jan 25, 2021 – Samsung Bioepis Co., Ltd. today announced the opening of its new headquarters in Korea’s ‘Bio Cluster’ of Songdo, located in the Incheon Free Economic Zone (IFEZ), a specially-designated economic zone in the city of Incheon. The new site is approximately 52,000 square feet, and will be the hub of Samsung Bioepis’ drive for development of next-generation biologic medicines. Construction of the new building was completed in December 2020.
“We are very excited to be opening our new headquarters which will serve as the foundation for the company’s next stage of growth. Our colleagues who were previously stationed in two campuses in Korea will be working together at the new headquarters to accelerate our passion for health”, said Christopher Hansung Ko, President and Chief Executive Officer, Samsung Bioepis. “With the new office equipped with the state-of-the art laboratories, we look forward to providing our high-quality biologic medicines with more agility and with stringent quality control so that patients around the world can have access to our proven medicines more quickly and more widely available.”
The newly established 12-story building will house approximately 1,000 employees, who will be working at the 17,300-square-foot laboratory space and 15,200-square-foot office space. Attached to the main building is a three-story ‘Welfare Center’ which includes 4,750-square-foot cafeteria, a gymnasium and a fitness center for employees to enjoy. Furthermore, the company has an onsite childcare center to support employees with young children.
Established in 2012, Samsung Bioepis has rapidly grown to have five biologic products in immunology and oncology with more than 215,000 patients treated with the company’s immunology products in Europe alone. The company is continuing its work to improve access to medicines through its unique ‘process innovation’ development platform and currently has five biologic candidates in its pipeline ranging from hematology and ophthalmology.
# # #
Yoon Kim: email@example.com